Myeloperoxidase in cardiovascular disease.
Myeloperoxidase (MPO) plays a central role in the innate immune system by generating leukocyte-derived oxidants to combat invading pathogens. These reactive intermediates have been increasingly recognized to be potentially deleterious, causing oxidative injury in inflammatory disease states such as cardiovascular disease. Recent evidence now suggests that circulating MPO can act as a clinical prognostic indicator for patients with cardiovascular disease.
Robert A
RA
Koeth
Virginia
V
Haselden
W H Wilson
WH
Tang
D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000097:blood* / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology; D005609:Free Radicals / Q000378:metabolism; D015870:Gene Expression; D006333:Heart Failure / Q000097:blood* / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D007113:Immunity, Innate; D009195:Peroxidase / Q000235:genetics / Q000378:metabolism*; D058226:Plaque, Atherosclerotic / Q000097:blood* / Q000175:diagnosis / Q000401:mortality / Q000503:physiopathology; D011379:Prognosis; D026361:Reactive Nitrogen Species / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D016019:Survival Analysis; D014443:Tyrosine / Q000378:metabolism
D015415:Biomarkers; D005609:Free Radicals; D026361:Reactive Nitrogen Species; D017382:Reactive Oxygen Species; C408694:tyrosine radical; D014443:Tyrosine; D009195:Peroxidase